ATE163548T1 - Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine - Google Patents

Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine

Info

Publication number
ATE163548T1
ATE163548T1 AT92910019T AT92910019T ATE163548T1 AT E163548 T1 ATE163548 T1 AT E163548T1 AT 92910019 T AT92910019 T AT 92910019T AT 92910019 T AT92910019 T AT 92910019T AT E163548 T1 ATE163548 T1 AT E163548T1
Authority
AT
Austria
Prior art keywords
hepatitis
strain
havs
relates
isolation
Prior art date
Application number
AT92910019T
Other languages
English (en)
Inventor
Reinhard Glueck
Stefan Brantschen
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of ATE163548T1 publication Critical patent/ATE163548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92910019T 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine ATE163548T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08

Publications (1)

Publication Number Publication Date
ATE163548T1 true ATE163548T1 (de) 1998-03-15

Family

ID=8206711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910019T ATE163548T1 (de) 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine

Country Status (10)

Country Link
EP (1) EP0542949B1 (de)
JP (1) JP3527238B2 (de)
AT (1) ATE163548T1 (de)
AU (1) AU662528B2 (de)
CA (1) CA2086832C (de)
DE (2) DE69224590T2 (de)
DK (1) DK0542949T3 (de)
ES (1) ES2056780T3 (de)
GR (2) GR930300089T1 (de)
WO (1) WO1992019268A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180110B1 (en) * 1992-09-18 2001-01-30 The United States Of America As Represented By The Department Of Health And Human Services Attenuated hepatitis a virus vaccine which grows in MRC-5 cells
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
EP1802746B1 (de) 2004-10-27 2011-05-04 Crucell Switzerland AG Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
PT71739B (en) * 1979-09-04 1982-01-26 Merck & Co Inc Process for preparing a cell culture of hepatitis a virus

Also Published As

Publication number Publication date
EP0542949A1 (de) 1993-05-26
GR3026612T3 (en) 1998-07-31
GR930300089T1 (en) 1993-09-30
AU662528B2 (en) 1995-09-07
DE542949T1 (de) 1993-09-02
DE69224590D1 (de) 1998-04-09
WO1992019268A1 (en) 1992-11-12
DE69224590T2 (de) 1998-10-15
DK0542949T3 (da) 1998-12-07
ES2056780T1 (es) 1994-10-16
JP3527238B2 (ja) 2004-05-17
JPH06500238A (ja) 1994-01-13
CA2086832C (en) 2007-05-01
ES2056780T3 (es) 1998-08-16
EP0542949B1 (de) 1998-03-04
CA2086832A1 (en) 1992-11-09
AU1743692A (en) 1992-12-21

Similar Documents

Publication Publication Date Title
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
EP0571613A4 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
ATE179716T1 (de) Verfahren zur bestimmung von peptiden, die immunologisch wichtigen epitopen von hcv zugehörig sind
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
YU9097A (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
FI870447A0 (fi) Htlv-iii-hoeljepeptider.
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
HUP9903770A2 (hu) Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
EP0881231A3 (de) HCV Peptidantigene und Verfahren zur Bestimmung von HCV
ATE127024T1 (de) Immunogene komplexe, insbesondere iscoms.
Weiland et al. Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide
ATE310014T1 (de) Hepatitis b-impfstoff
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
ATE163548T1 (de) Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine
EP0967223A3 (de) Hepatitis C Virus Peptidantigene und Verfahren zur Bestimung von Hepatitis C Virus (HCV)
ATE518879T1 (de) Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
ES2132115T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c y su procedimiento de utilizacion.
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
DK142488D0 (da) Treponema hyodysenteriae antigener, vaccine indeholdende disse antigener eller fragmenter deraf og metode til bestemmelse af antistoffer over for treponema hyodysenteriae

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification